---
title: "Basilea publishes investor presentation on anti-infectives strategy, pipeline focus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291222977.md"
description: "Basilea Pharmaceutica AG published an investor presentation outlining its asset-light anti-infectives strategy. Key highlights include a 27% YoY sales increase for Cresemba to USD 782 million and the US launch of Zevtera via Innoviva. The pipeline focuses on phase 3 trials for fosmanogepix and ceftibuten-ledaborbactam. The company emphasizes non-dilutive R&D funding, citing approximately USD 440 million committed, including BARDA support."
datetime: "2026-06-30T04:11:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291222977.md)
  - [en](https://longbridge.com/en/news/291222977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291222977.md)
generator: "portal-rs"
---

# Basilea publishes investor presentation on anti-infectives strategy, pipeline focus

-   Basilea outlined an asset-light, partnership-led anti-infectives model built around royalties, milestones, limited selling spend, minimal capex. \* Cresemba in-market sales USD 782 million for April 2025 to March 2026, up 27% year-on-year; marketed in 76 countries. \* Zevtera launched in the US in July 2025 via Innoviva Specialty Therapeutics; US market exclusivity runs until April 2034. \* Pipeline priorities include phase 3 fosmanogepix in invasive candidiasis and invasive mold infections; ceftibuten-ledaborbactam phase 3 start targeted early 2027. \* Non-dilutive R&D funding cited at about USD 440 million committed, including about USD 130 million; Zevtera supported by USD 111 million BARDA funding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [INVA.US](https://longbridge.com/en/quote/INVA.US.md)

## Related News & Research

- [Connor Clark & Lunn Investment Management Ltd. Acquires Shares of 52,479 Innoviva, Inc. $INVA](https://longbridge.com/en/news/297479268.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)
- [Basilea publishes investor presentation on anti-infectives strategy and pipeline progress](https://longbridge.com/en/news/296180070.md)
- [Eiffage announces availability of H1 2026 results report](https://longbridge.com/en/news/297066901.md)
- [TFF Group announces availability of FY 2025/2026 annual financial report](https://longbridge.com/en/news/297542297.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**